Description du projet
Atténuer significativement le syndrome métabolique
Le syndrome métabolique (SMet) touche plus d’un quart de la population mondiale et peut entraîner une série de problèmes de santé graves, dont les accidents vasculaires cérébraux, le cancer, le diabète, la maladie d’Alzheimer et les maladies cardiaques. L’obésité viscérale est un signe clé et un facteur contribuant à la résistance à l’insuline, l’une des principales causes du SMet. Le projet INNOPREFAT, financé par l’UE, entend mettre au point une solution naturelle pour lutter contre le SMet en créant une formulation alimentaire baptisée MetabolAid®. Le produit sera fabriqué à partir d’extraits de plantes par Monteloeder, une société espagnole réputée. MetabolAid® vise à prévenir et à traiter l’obésité et le SMet en utilisant une formule synergique unique, en exploitant des données scientifiques, en faisant preuve d’efficacité et en instaurant une chaîne d’approvisionnement transparente.
Objectif
Monteloeder is a global developer, manufacturer and distributor of ingredients and formulations for the nutrition and cosmetics industry. It is committed to identifying and developing safe and effective ingredients derived from natural plants that deliver measureable benefits to consumers. Founded in 1996, Monteloeder today has sales in more than 38 countries and operates offices in Europe, US and Asia.
INNOPREFAT is the result of a long process led by Monteloeder to discover a natural solution to address one of the major epidemics of our time: Metabolic Syndrome (MetS). MetS can lead to serious diseases and conditions, including diabetes type-2, stroke, Alzheimer’s, cancer and heart disease. It affects more than 25% of the world’s population and represents a major and escalating global public health problem and clinical challenge. In Europe, about 8-18% of total adult healthcare expenditure is metabolic syndrome related.
The Business Model and the solution (MetabolAid®) are built around three dimensions: 1. A superior quality product based on a synergistic blend of two herbal extracts, which is supported by an extensive and rigorous scientific programme that demonstrates its effectiveness in improving MetS, as well as its safety and its economic viability. 2. A fully traceable, transparent and efficient supply chain, which guarantees that the product is natural, sustainably produced, completely safe and that it can be included in the main food matrices. 3. Global marketing approach includes a novel and original strategy: we will support our B2B clients with mobile phone health technology to manage end-consumer’s experience with the product and improve their levels of compliance, which in turn will enhance efficacy.
Monteloeder believes that those are the dimensions that will determine how ingredients must be designed, developed, produced and marketed to address the big changes in consumer preferences that are already taking place in the market.
Champ scientifique
- natural sciencescomputer and information sciencescomputer securitydata protection
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
- medical and health sciencesclinical medicinehepatology
- medical and health scienceshealth sciencesnutritionobesity
Mots‑clés
Programme(s)
- H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme
- H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy
- H2020-EU.3.2.1. - Sustainable agriculture and forestry
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
03203 Elche
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.